Numerous murine models of heart failure (HF) have been described, many of which develop progressive deterioration of cardiac function. We have recently demonstrated that several of these can be "rescued" or prevented by transgenic cardiac expression of a peptide inhibitor of the β-adrenergic receptor kinase (βARKct). To uncover genomic changes associated with cardiomyopathy and/or its phenotypic rescue by the βARKct, Multiple statistical analyses demonstrated significant differences between all groups, and further demonstrated that βARKct Rescue returned gene expression toward that of Normal. In our statistical analyses, we found that the HF phenotype is blindly predictable based solely on gene expression profile. To investigate the progression of HF, LV gene expression was determined in young mice with mildly diminished cardiac function and in older mice with severely impaired cardiac function. Interestingly, mild and advanced HF mice shared similar gene expression profiles and, importantly, the mild HF mice were predicted as having a HF phenotype when blindly subjected to our predictive model described above. These data not only validate our predictive model, but further demonstrate that, in these mice, the HF gene expression profile appears to already be set in the early stages of HF progression. Thus, we have identified methodologies that have the potential to be used for predictive genomic profiling of cardiac phenotype, including cardiovascular disease.
Introduction
Several genetic mouse models of heart failure (HF) have recently been described involving mutation, ablation or cardiac overexpression of different genes. In particular, ablation of the muscle LIM protein gene (MLP -/-), a muscle-restricted cytoarchitectural protein (2) , or myocardial-targeted transgenic overexpression of calsequestrin (CSQ), a high-capacity sarcoplasmic reticulum Ca 2+ binding protein (6, 15) , result in genetic mouse models of HF. Both models develop cardiomyopathy and significant left ventricular (LV) dysfunction, although the CSQ model is a much more aggressive phenotype that results in premature death by 9-16 weeks of age (6, 15) . The MLP -/-mice develop dilated cardiomyopathy between 3-6 months of age (2) . Both mouse models of HF also exhibit several molecular manifestations present in the failing human heart, including numerous biochemical abnormalities in the β-adrenergic receptor (β-AR) system, such as functional receptor uncoupling, enhanced expression and activity of the β−AR kinase (βARK1) and loss of β-AR inotropic reserve (25) .
βARK1, a member of the G protein-coupled receptor (GPCR) kinase (GRK)
family, targets and phosphorylates agonist-occupied GPCRs, including myocardial β-includes enhanced survival and cardiac function, adding further evidence of the critical role of βARK1 in the development of HF via its regulation not only of β-ARs but potentially other cardiac GPCRs or signaling effectors (25) .
These relatively well-characterized mouse models of HF and their βARKct-mediated phenotypic rescue provide powerful models to investigate the development, progression and rescue of the HF phenotype at the level of ventricular gene expression.
Recently, there have been reports of differential gene expression in various phenotypes of both rodent and human HF (3, 4, 8, 10, 14, 20, 23, 29) as well as in humans before and after salutary mechanical circulatory support (5) . Our goal for the current study was to employ both substantial sample size and robust statistical methods to establish statistically significant results and predictive capability, not only for comparison of the non-failing and failing heart, but also for the progression and rescue of HF.
To address these issues, we performed oligonucleotide microarray analysis of Rescue and Tg mice by gene expression profile and also identify specific genes significantly associated with each phenotype. Further, we investigated changes in LV gene expression that may be associated with the progression of HF using both young mice with limited ventricular dysfunction and adult mice with advanced HF, and further validated our predictive models with these mice.
Materials and Methods
Tissue Sampling and RNA Extraction LV myocardial tissue was dissected out of hearts freshly harvested from 53 individual mice, weighed and immediately frozen in liquid nitrogen then stored at -80 0 C.
All animal procedures and tissue harvesting were performed in concordance with NIH guidelines and approved Duke University animal procedures.
Mice were genotyped, and cardiac function/phenotype was determined (by echocardiography) according to previously published protocols (11, 24) prior to inclusion in the microarray experiments. Total LV RNA was extracted using a tissue disruptor and Ultraspec RNA reagent according to manufacturer protocol (Biotecx, Houston, TX).
Total RNA quality was first assessed by 1.2% agarose-formaldehyde gel electrophoresis, followed by Agilent RNA 6000 chips coupled with the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA), where 500 ng were used to determine the 28S:18S rRNA ratio. All RNA used in the current study met the minimum requirements set of a 1.8 ratio for 28S:18S rRNA. RNA aliquots were stored at -80 0 C prior to use.
Northern Blot
Northern Blot analysis of gene expression was performed using 10 µg total RNA as described previously (1) .
Microarray Analysis
Expression analysis was performed using Affymetrix Murine 11K GeneChips, which represent ~11,000 known genes or novel clones (Affymetrix, Santa Clara, CA).
Target cRNA was prepared according to manufacturer's protocol. Arrays were hybridized with the targets at 45 0 C for 16 h, then washed and stained using the GeneChip Fluidics Station. Arrays were visualized with the GeneChip scanner, and scanning results processed by the GeneChip Expression Analysis Algorithm (version 3.2), with a target intensity of 500 (Affymetrix, Santa Clara, CA). Chips were processed using the same lot of reagents, equipment, fluidics station, and scanner, to minimize experimental chip-tochip variability. Scaling factors for each chip were within 10% of the mean of all chips.
Statistical Analyses
Average difference values (perfect match to mismatch, or PM:MM ratios)
provided by the Affymetrix analysis from each chip were the starting point for all statistical analyses. ANOVA, t-test and multi-dimensional scaling (MDS) of total gene expression profiles were performed using Partek software, (Partek, Inc., St. Charles, MO;
http://www.partek.com/). For two-sample unequal variance t-test and ANOVA, corrected for multiple comparisons, all data for each chip was individually linearized (individual data points for the entire data set for each chip reduced on a linear scale into a range of 0-1) and log 2 transformed, then this subset of results was compared to a list of genes with low false discovery rate determined to be significant by t-statistic score and class permutation tests (see below). MDS is a data structure visualization and analysis tool, which, in the simplest of terms, is a mapping of high-dimensional data (~11,000 genes per animal) into low-dimensional space, such that the distances between points mapped in low-dimensional Euclidean space represent the similarities, dissimilarities or distances of the original data. In this case, distance between points in the images approximates dissimilarity between data in high-dimensional space (D R ). Herein, metric MDS was performed based on Pearson dissimilarity (defined as (1 -r)/2, where r is the Pearson correlation) and mapped into 2-dimensional space (initialized with points drawn randomly from a uniform distribution in the range of -1 to 1) (see (9) 
Bayesian Regression Statistics
Predictive Bayesian regression modeling using permutation-tested t-statistic determined priors for classifying the mouse models based on gene expression profiles can be rigorously evaluated by cross validation. We use the regularized linear regression model as described (28, 33) . To avoid bias toward only the highest expressed genes (linear models) or lowest expressed genes (logarithms), we normalized the data using the variance stabilization technique(13). Normalization is followed by a predictive binary classification (ie. 0=Normal, 1=HF), based on a Bayesian Regression Model designed for binary class prediction from gene expression data, initialized using the 100 genes with the highest t-score from a permutation-tested t-statistic. Importantly, the predictive power of 
Results
Our current study was perfomed based on the following phenotypic groups of mice that have previously been extensively characterized (2, 6, 11, 15, 16, 24, 25) : 1) 12
Normal ( Table 1 , Methods and (33)). Thus, we determined that it was feasible and reasonable to combine mice from slightly different backgrounds into phenotypic groups for our subsequent analyses as delineated above.
To determine the genomic profile of failing and non-failing murine myocardium, Specific genes associated with cardiomyopathy were determined by a corrected, unpaired t-test comparing the Normal and HF groups, which included a number of novel genes not previously associated with HF. Importantly, this list included several known marker genes of HF from several functional categories, such as ANF, BNP, β-MHC, skeletal-α-actin, FHL1, HB-EGF, desmin, osteoblast-specific factor 2, myosin light chain 1, laminin, collagen and plasminogen activator inhibitor (3, 7, 12, 20) (see Table 1 , and Supplemental Data Table 2 ). Tables 2 and 3 ). Therfore, we are able to detect by multiple statistical methods that there is an overall LV gene expression profile that can not only distinguish, but also accurately predict, the HF phenotype independent of genetic background or etiology.
Previously, myocardial-targeted expression of βARKct in mice (Tg) has been demonstrated to result in increased cardiac function and enhanced β-AR responsiveness (17). However, in the current study, there was no significantly detectable difference at the level of gene expression between Normal and Tg mice using all methods described above (data not shown). Thus, minimal changes in gene expression appear to accompany the βARKct cardiac phenotype in non-HF mice.
We were particularly interested in discovering changes in the LV gene expression profile (Fig. 2) .
A strikingly small number of genes were found to be differentially expressed as determined by a corrected t-test of normalized data (Table 3 ), including few that have been previously characterized in the HF phenotype. Surprisingly, both early-and advanced-stage HF mice were classified as HF by MDS ( Figure 3A) , and there was no predictive difference between the early-and advance-stage HF groups based on their gene expression profile. Importantly, both early and advanced-stage HF mice were blindly predicted to be of a HF phenotype/gene expression profile using the predictive model described above followed by blind (ie. not pre-classified) addition of the data from the early-and advanced-stage samples and more rigorous full cross-validation, demonstrating the applicability of this methodology to blindly predict phenotype based solely on gene expression ( Figure 3B ).
The above data validate our predictive model, and suggest, using these mouse models of HF, that the gene expression profile of HF is set at a very early stage in the pathogenesis of this disease. As anticipated from this predictive analysis, a majority of the top 20 genes significantly associated (ie. estimated 0% false discovery rate) with both early-and advanced-stage HF were shared in common with those previously determined in the analysis of Normal vs. HF (Supplemental Data Table 5 ). There was no correlation of chromosomal location associated with any of the lists of differential gene expression described herein (data not shown).
Secondary validation of oligonucleotide microarray expression data was carried out by Nothern Blot analysis for several genes, including the HF marker genes ANF and BNP. Data obtained by Northern Blot was consistently qualitatively concordant with that found by the oligonucleotide microarrays (Figure 4 ), similar to qualitative concordance found previously by others (8, 18, 19, 27, 33) . These results demonstrate similar qualitative regulation of LV gene expression between phenotypic groups from both genetic models of HF. For further secondary validation, and to test the correlation between mRNA and protein expression, immunoblot analysis was performed. We chose the g-protein G αo , as its substantial upregulation was one of our top 20 overall predictors of the HF phenotype (Supplemental Data Table 5 ), and has also previously been associated with muscarinic regulation of L-type calcium channels (31). Indeed, there was good correlation between up-regulation of both mRNA and protein expression in HF as compared to Normal mice ( Figure 5 ).
Discussion
The current study provides substantial insight into the development, progression and rescue of murine HF at the level of differential myocardial gene expression. We have described and validated methods that can blindly predict HF phenotype at both early and advanced stages based on gene expression data, which suggests that the gene expression profile of HF is set very early in the disease progression. Our study provides The statistical detection of differential gene expression of numerous HFassociated genes provides a 2-fold validation of our approach. First, it validates these mouse models as appropriate genetic models of HF in which to further elucidate the molecular mechanisms of HF and test novel therapeutic targets. Second, it verifies that our approach using oligonucleotide microarrays analyzed with robust statistical methods indeed identifies genes significantly associated with and predictive of phenotype.
Overall, we believe these data provide a statistically valid benchmark for future comparisons of murine cardiac phenotype with gene expression profile.
Our approach of using multiple statistical methods, including blind and crossvalidated prediction of phenotype, enhances the validity of the data, in that each method generally reaches similar conclusions. Although there is some divergence in specific genes identified by each statistical method, genes that are common to multiple analytical methods are quickly recognized as the most favorable targets for future investigation (See Supplemental Data Tables 2-5 ). We have identified gene expression profiles germane to each phenotype, many of which are targets of current and future investigation in our
laboratory.
An important finding of our study was that the phenotypic rescue of HF by βARKct expression in the Rescue mice is significantly associated with a return toward
Normal gene expression, which we believe further validates βARK1 inhibition as a therapeutic target. Interestingly, in the βARKct Tg mice, which demonstrate enhanced cardiac function (17), non-significant but qualitative salutary expression of a few marker genes of HF was detected when compared to Normal, such as decreased skeletal-α-actin and cardiac-α-actin (data not shown). Our data suggest that even in normal myocardium, the βARKct is both enhancing cardiac functional response and producing subtle yet potentially beneficial effects on gene expression. This beneficial effect on gene expression was more profoundly manifested in the analysis of Rescue mice, where the βARKct not only rescued the functional phenotype (11, 24) , but also resulted in a significant shift of the HF gene expression profile toward Normal, which although not blindly predictive, was detected by all of our other statistical methdologies. Of particular interest, changes in gene expression accompanying the (βARKct) Rescue of HF, particularly decreased ANF and β-MHC, were similar to those seen in human HF patients that responded to β-blocker therapy (21) . These data suggest that improved contractile function may be the stimulus for these significant changes in gene expression, since the βARKct alone (Tg) did not significantly change the LV gene expression profile. Future studies will test this hypothesis by using our methods on other non-βARKct rescued murine HF phenotypes (22, 26) .
Overall, our current study considered two separate mouse models of HF and
Rescue as a single group, to allow investigation of the gene expression profile germane to
Normal, HF, and Rescue, along with the development of HF, independent of genetic cause or HF etiology. Although beyond the scope of the this report, it will be important to further investigate the similarities and differences between each of these models of HF and their Rescue, as well as to investigate the differences between etiologies of human HF. In our current investigation, we have identified methodologies, including novel statistical and predictive analyses, that demonstrate the potential for using multifactoral gene expression profiling coupled with all other available patient data as a predictive tool for cardiovascular diseases such as HF. 
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